Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
QuintilesIMS
UBS
Express Scripts
Covington
Citi
Teva
AstraZeneca
Merck

Generated: February 18, 2019

DrugPatentWatch Database Preview

HERCEPTIN Drug Profile

« Back to Dashboard

Summary for Tradename: HERCEPTIN
Pharmacology for HERCEPTIN
Mechanism of ActionHER2/Neu/cerbB2 Antagonists

US Patents for HERCEPTIN

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Try a Free Trial Novartis AG (Basel, CH) ➤ Try a Free Trial RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Try a Free Trial Array BioPharma Inc. (Boulder, CO) ➤ Try a Free Trial RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Try a Free Trial ACADEMIA SINICA (Taipei, TW) ➤ Try a Free Trial RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Try a Free Trial XUANZHU PHARMA CO., LTD. (Jinan, Shandong Province, CN) ➤ Try a Free Trial RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Try a Free Trial Yeda Research and Development Co. Ltd. (Rehovot, IL) ➤ Try a Free Trial RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Try a Free Trial SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) ➤ Try a Free Trial RX Orphan search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for HERCEPTIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
442 Finland ➤ Try a Free Trial
18/2015 Austria ➤ Try a Free Trial PRODUCT NAME: IBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ; REGISTRATION NO/DATE: EU/1/14/945 20141021
273 5026-2016 Slovakia ➤ Try a Free Trial PRODUCT NAME: IBRUTINIB VO VSETKYCH FORMACH CHRANENYCH ZA- KLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/945 20160530
212 50002-2015 Slovakia ➤ Try a Free Trial PRODUCT NAME: POMALIDOMID; REGISTRATION NO/DATE: EU/1/13/850/001 - EU/1/13/850/004 20130808
PA2015017 Lithuania ➤ Try a Free Trial PRODUCT NAME: IBRUTINIBUM; REGISTRATION NO/DATE: EU/1/14/945 20141021
1590021-0 Sweden ➤ Try a Free Trial PRODUCT NAME: IBRUTINIB ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/14/945 20141023
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Julphar
Dow
Moodys
McKesson
Deloitte
McKinsey
Federal Trade Commission
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.